Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molnupiravir Tablet Bioequivalence and Food Effect Study
NCT06615869Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2023
- Primary completion
- Feb 2023
- Modality
- RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of molnupiravir in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity, Area Under the Concentration-Time Curve From Time Zero to Last Measurable Timepoint and 2 more. Started Jan 2023; status: completed.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06615869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06615869.